An FDA-mandated cardiovascular safety trial of gout drug febuxostat (Adenuric) has found an unexpected increase in all-cause mortality but no difference in major cardiovascular events, compared to allopurinol. The CARES trial was initiated at the behest of the FDA to investigate a modest increase in cardiovascular events seen in earlier trials of febuxostat compared to ...
Febuxostat cardiovascular safety trial raises more questions than answers
By Michael Woodhead
14 Mar 2018